Finance

Lists
Why is CRBU down 2,11%?
Dive Deeper
CRBU:NASDAQ
Caribou Biosciences Inc
0,46 USD
-2,11%
(-0,0099) 1D
0,46 USD
+1,06% (+0,0049)
After hours
Closed: 14-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBU...
Open
0,48 USD
High
0,48 USD
Low
0,44 USD
Mkt. cap
49,33 млн
Avg. vol.
3,67 млн
Volume
3,70 млн
52-wk high
3,53 USD
52-wk low
0,44 USD
EPS
-1,08 USD
Beta
2,31
Shares outstanding
107,21 млн
No. of employees
97
Open
0,48 USD
High
0,48 USD
Low
0,44 USD
Mkt. cap
49,33 млн
Avg. vol.
3,67 млн
Volume
3,70 млн
52-wk high
3,53 USD
52-wk low
0,44 USD
EPS
-1,08 USD
Beta
2,31
Shares outstanding
107,21 млн
No. of employees
97
News stories
From web sources and news partners
About Caribou Biosciences Inc
CEO-
Employees97
Founded2011-ж., 1-янв.
HeadquartersБеркли, Калифорния, Америка Кошмо Штаттары
Sector-
Websitecariboubio.com
Analyst ratings
Based on 6 analysts giving stock ratings to CRBU in the past 3 months
Buy
Buy
2
Hold
4
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CRBU in the last 3 months.
Highest
Current 0,46 USD
8,00 USD (+1 638,75%)
Average
3,75 USD (+715,04%)
Lowest
1,00 USD (+117,34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Hold
Downgraded
-
-
10/08/2026
Daina Graybosch
Leerink Partners
Hold
Downgraded
1,00 USD
+117,3%
10/07/2026
Luca Issi
RBC Capital
Hold
Downgraded
1,00 USD
+117,3%
10/06/2026
Leah R. Cann
Brookline Capital Markets
Hold
Downgraded
-
-
10/06/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
5,00 USD
+986,7%
08/14/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
8,00 USD
+1 638,8%
08/13/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
13,00 USD
+2 725,5%
03/09/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
7,00 USD
+1 421,4%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
4,00 USD
+769,4%
03/06/2026
William Maughan
Clear Street
Buy
Maintained
13,00 USD
+2 725,5%
03/06/2026
Last report
2026-ж., 13-авг.
Fiscal period
Q2 2026
-0,24 USD / -0,31 USD
+21,74%beat
Revenue / Est. (USD)
1,50 млн / 2,25 млн
-33,25%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
2,20 млн
3,94 млн
2,40 млн
1,50 млн
Cost of goods sold
22,40 млн
23,82 млн
20,61 млн
18,94 млн
Cost of revenue
22,40 млн
23,82 млн
20,61 млн
18,94 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,20 млн
8,58 млн
8,07 млн
7,90 млн
Operating expense
9,20 млн
8,58 млн
8,07 млн
7,90 млн
Total operating expenses
31,60 млн
32,39 млн
28,68 млн
26,84 млн
Operating income
-29,40 млн
-28,45 млн
-26,28 млн
-25,34 млн
Other non operating income
-
42,00 миң
-
-
EBT including unusual items
-27,55 млн
-27,04 млн
-25,08 млн
-24,28 млн
EBT excluding unusual items
-27,55 млн
-27,04 млн
-25,08 млн
-24,28 млн
Income tax expense
-
-550,00 миң
-
-
Effective tax rate
-
2,03%
-
-
Other operating expenses
-
-
-
-
Net income
-27,55 млн
-26,49 млн
-25,08 млн
-24,28 млн
Net profit margin
-1 253,32%
-672,11%
-1 046,52%
-1 619,88%
Earnings per share
-
-
-0,26
-0,24
Interest and investment income
1,85 млн
1,37 млн
1,20 млн
1,06 млн
Interest expense
-
-
-
-
Net interest expenses
1,85 млн
1,37 млн
1,20 млн
1,06 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-28,77 млн
-27,77 млн
-25,63 млн
-24,71 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору